AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 Mar 2022 07:00 AM
RNS
Settlement of patent litigation for Ultomiris
14 Mar 2022 07:05 AM
RNS
Lynparza approved in US for early breast cancer
14 Mar 2022 07:00 AM
RNS
Update on US review of Fasenra in nasal polyps
09 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
07 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
01 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
01 Mar 2022 03:00 PM
RNS
Total Voting Rights
01 Mar 2022 07:00 AM
RNS
AstraZeneca and Neurimmune close deal for NI006
23 Feb 2022 07:00 AM
RNS
Filing of Form 20-F with SEC
22 Feb 2022 11:00 AM
RNS
Chair succession planning update and Annual Report
21 Feb 2022 07:00 AM
RNS
Enhertu improves PFS and OS in HER2-low BC
16 Feb 2022 07:00 AM
RNS
Saphnelo approved in EU for SLE
15 Feb 2022 07:00 AM
RNS
Lynparza combo delays progression risk in prostate
11 Feb 2022 03:30 PM
RNS
Director/PDMR Shareholding
10 Feb 2022 07:00 AM
RNS
AZN: Full year and Q4 2021 results
01 Feb 2022 03:00 PM
RNS
Total Voting Rights
19 Jan 2022 07:05 AM
RNS
Imfinzi improves survival in biliary tract cancer
19 Jan 2022 07:00 AM
RNS
Imfinzi combo shows unprecedented survival in HCC
17 Jan 2022 07:00 AM
RNS
Enhertu granted Priority Review for breast cancer
07 Jan 2022 07:00 AM
RNS
AstraZeneca and Neurimmune sign deal for NI006
05 Jan 2022 07:00 AM
RNS
Transfer of rights to Eklira, Duaklir completed
04 Jan 2022 03:00 PM
RNS
Total Voting Rights
29 Dec 2021 07:00 AM
RNS
AstraZeneca and Ionis close eplontersen deal
21 Dec 2021 07:00 AM
RNS
Ultomiris accepted for FDA Priority Review for gMG
20 Dec 2021 07:05 AM
RNS
Tezspire approved in the US for severe asthma
20 Dec 2021 07:00 AM
RNS
Saphnelo recommended for EU approval for SLE
15 Dec 2021 03:00 PM
RNS
Director/PDMR Shareholding
09 Dec 2021 07:00 AM
RNS
Evusheld US FDA EUA
07 Dec 2021 07:00 AM
RNS
AstraZeneca, Ionis to collaborate on eplontersen
01 Dec 2021 03:00 PM
RNS
Block listing Interim Review
01 Dec 2021 03:00 PM
RNS
Total Voting Rights
30 Nov 2021 07:00 AM
RNS
Lynparza granted FDA Priority Review for OlympiA
15 Nov 2021 04:00 PM
RNS
Director/PDMR Shareholding
12 Nov 2021 07:00 AM
RNS
AZN: Year to date and Q3 2021 results
01 Nov 2021 03:00 PM
RNS
Total Voting Rights
01 Nov 2021 07:00 AM
RNS
AstraZeneca to transfer rights to Eklira, Duaklir
25 Oct 2021 07:00 AM
RNS
Imfinzi improved survival in biliary tract cancer
18 Oct 2021 07:00 AM
RNS
AZ recommends ADS holders reject mini-tender offer
15 Oct 2021 07:00 AM
RNS
Imfinzi & tremelimumab improved OS in liver cancer
11 Oct 2021 07:00 AM
RNS
AZD7442 PhIII trial positive in COVID outpatients
04 Oct 2021 07:00 AM
RNS
Enhertu granted BTD for breast cancer
01 Oct 2021 03:00 PM
RNS
Total Voting Rights
30 Sep 2021 04:00 PM
RNS
Director/PDMR Shareholding
29 Sep 2021 07:00 AM
RNS
AstraZeneca to fully acquire Caelum Biosciences
28 Sep 2021 07:00 AM
RNS
Saphnelo approved in Japan for SLE
24 Sep 2021 07:00 AM
RNS
Lynparza PROpel trial meets primary endpoint
23 Sep 2021 07:00 AM
RNS
Board Committee Change
23 Sep 2021 07:00 AM
RNS
New Sustainability Committee of the Board
21 Sep 2021 07:00 AM
RNS
AstraZeneca $360m Irish manufacturing investment
20 Sep 2021 07:00 AM
RNS
Enhertu reduced risk of disease progression by 72%
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings